The treatment of HIV infection has been radically altered by the use of combination anti-retroviral chemotherapy including protease inhibitors. These agents in combination with reverse transcriptase inhibitors produce profound declines in plasma viral RNA, increases in CD/4 counts and improved clinical outcomes. This therapy provides the prospect for long term survival and even disease eradication. At the same time, if these medications are taken in inadequate amount or if the regimen dosing is irregular, the therapeutic benefit is lost and antiviral resistance develops. Protease inhibitors require rigorous dosing schedules, most commonly added to already complex medications regimens. Furthermore, these medications cause trouble side effects and have substantial drug interactions. The patients taking these medications often are functionally compromised with poor health status and may be cognitively impaired. These factors makes the successful treatment of HIV disease less an issue of the availability of potent pharmacological therapeutics and more dependent on patient ability to adhere to a complex medication regiment over time. However, rigorous methods of measuring adherence to anti-retroviral medication are not widely available and most clinical trials have employed minimal, if any, evaluation of medication adherence. The Medication Adherence Core is validating interview-based methodology to measure adherence based on newly developed items and work done in the ACTG and HCSUS studies. These instruments measure patient adherence to work with HIV clinical trials and cohort studies at UCLA to (1) identify opportunities to measure medication adherence, (2) provide and customize instruments for incorporation into existing and planned studies. (3) assist in design of data collection and analysis strategies to measure adherence and factors associated with adherence, and (4) adapt previously validated instruments for new populations (such as pediatrics) and clinical settings. In addition, the Medication Adherence Core will work with clinical trial investigators to develop interventions to enhance adherence and to measure the effects of these interventions. In addition, with the Behavioral Adherence Recruitment and Retention Core, this Core will create coherent assessment modules of medical and behavioral adherence for UCLA investigators. Both Cores will constitute the Health Behavior and Outreach Program of the CFAR.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI028697-11
Application #
6324583
Study Section
Project Start
2000-07-01
Project End
2001-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
11
Fiscal Year
2000
Total Cost
$142,758
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Seang, Sophie; Kelesidis, Theodoros; Huynh, Diana et al. (2018) Low Levels of Endothelial Progenitor Cells and Their Association with Systemic Inflammation and Monocyte Activation in Older HIV-Infected Men. AIDS Res Hum Retroviruses 34:39-45
Kojima, Noah; Klausner, Jeffrey D (2018) Fight Fire With Fire: Innovations to Address Syphilis Among Men Who Have Sex With Men. Sex Transm Dis 45:e85-e86
Black, David S; Cole, Steve W; Christodoulou, Georgia et al. (2018) Genomic mechanisms of fatigue in survivors of colorectal cancer. Cancer 124:2637-2644
Ziyad, Safiyyah; Riordan, Jesse D; Cavanaugh, Ann M et al. (2018) A Forward Genetic Screen Targeting the Endothelium Reveals a Regulatory Role for the Lipid Kinase Pi4ka in Myelo- and Erythropoiesis. Cell Rep 22:1211-1224
Walser, Tonya C; Jing, Zhe; Tran, Linh M et al. (2018) Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. Cancer Res 78:1986-1999
Fulcher, Jennifer A; Shoptaw, Steven; Makgoeng, Solomon B et al. (2018) Brief Report: Recent Methamphetamine Use Is Associated With Increased Rectal Mucosal Inflammatory Cytokines, Regardless of HIV-1 Serostatus. J Acquir Immune Defic Syndr 78:119-123
Chua, Bernadette Anne; Ngo, Jamie Ann; Situ, Kathy et al. (2018) Protein S and Gas6 induce efferocytosis of HIV-1-infected cells. Virology 515:176-190
Kojima, Noah; Klausner, Jeffrey D (2018) Improving management of sexually transmitted infections in those who use pre-exposure prophylaxis for human immunodeficiency virus infection. AIDS 32:272-275
Khamaikawin, Wannisa; Shimizu, Saki; Kamata, Masakazu et al. (2018) Modeling Anti-HIV-1 HSPC-Based Gene Therapy in Humanized Mice Previously Infected with HIV-1. Mol Ther Methods Clin Dev 9:23-32
Allyn, P R; O'Malley, S M; Ferguson, J et al. (2018) Attitudes and potential barriers towards hepatitis C treatment in patients with and without HIV coinfection. Int J STD AIDS 29:334-340

Showing the most recent 10 out of 942 publications